Corcept Therapeutics (CORT) EBT Margin (2012 - 2026)

Corcept Therapeutics has reported EBT Margin for 15 years, with the latest figure at 17.93% in Q2 2026.

• Quarterly EBT Margin rose 163.0% year-over-year to 17.93% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.17% (down 1445.0% YoY) and the FY2025 annual result came in at 8.73%, down 1519.0% from the prior year.
• EBT Margin grew to 17.93% in Q2 2026 per CORT's latest filing, from 27.12% in the prior quarter.
• Over five years, EBT Margin peaked at 32.44% in Q3 2022 and troughed at 27.12% in Q1 2026.
• A 5-year average of 18.83% and a median of 23.7% in 2022 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2024 and 2026: EBT Margin jumped 639 bps in 2024, then plunged 3323 bps in 2026.
• Over 5 years, EBT Margin stood at 23.56% in 2022, then rose by 15 bps to 27.18% in 2023, then tumbled by 35 bps to 17.57% in 2024, then sank by 72 bps to 4.9% in 2025, then soared by 266 bps to 17.93% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 17.93%, 27.12%, and 4.9% for Q2 2026, Q1 2026, and Q4 2025 respectively.